Salmonella diarizonae hos dyr i Norge. Konsekvenser for dyr og mennesker.

Source at https://vkm.no/S. diarizonae er et subspecies av Salmonella som påvises endemisk hos sau i enkelte regioner i Norge. Det er derfor stilt spørsmål om mikrobens potensielle og reelle betydning for både folke- og dyrehelsen. Det er også stilt spørsmål ved påstanden om at Norge har en tilnærmet salmonella-fri husdyrpopulasjon kan forsvares når S. diarizonae påvises relativt ofte hos sau i Norge i dag. Mattilsynet har på ovennevnte bakgrunn bedt Vitenskapskomiteen for mattrygghet (VKM) om en risikovurdering. Det ble en ad hoc arbeidsgruppe nedsatt for å gjennomføre oppdraget. Vurderingen er utført av faggruppe for hygiene og smittestoffer ved VKM.S. diarizonae is a sub-species of Salmonella that has been demonstrated to be endemic in sheep in various regions of Norway. Questions have therefore been posed regarding this microbe’s potential and actual significance regarding both human and animal health. It has also been questioned whether the contention that Norway’s domestic animal population is almost Salmonella-free can be defended when S. diarizonae is demonstrated relatively frequently in sheep in some regions. Based on this background, The Norwegian Scientific Committee for Food Safety, Panel on Biological Hazards, was asked by the Norwegian Food Safety Authority for a risk assessment regarding. In response, an ad hoc Working Group of experts wasappointed with the mandate to draft a risk assessment regarding this issue

Risk assessment on use of Lactobacillus rhamnosus (LGG) as an ingredient in infant formula and baby foods (II)

publishedVersio

Risk assessment on use of Lactobacillus rhamnosus (LGG) as an ingredient in infant formula and baby foods (II)

Source at https://vkm.no/On 10. March 2006 , The Norwegian Food Safety Authority (Mattilsynet) decided that, on the basis of VKM’s previous risk assessment (2005), Nutramigen 1 with Lactobacillus rhamnosus GG (LGG) could not be marketed in Norway as medical foods for infants (0-4 months). In addition, The Norwegian Food Safety Authority (Mattilsynet) decided (08. November 2006) to withdraw permission for marketing ofNutramigen 2 with LGG, which is a milk supplement for infants aged between 4 and 6 months, with cow’s milk and soy protein allergy. On 13. December 2006, Mead Johnson Nutritionals appealed against this decision from The Norwegian Food SafetyAuthority (Mattilsynet). The Norwegian Food Safety Authority forwarded the appeal from the companies, asked the VKM Panel on biological hazards and the VKM Panel on nutrition, dietetic products, novel food and allergy, for a new risk assessment including the new data provided in the appeal.Basert på VKMs tidligere risikovurdering fra 2005, bestemte Mattilsynet 10. mars 2006 atNutramigen 1 med LGG ikke kunne markedsføres som næringsmiddel til spesielle medisinske formål (0-4 måneder) i Norge. I tillegg trakk Mattilsynet tilbake tillatelsen (08. november, 2006) til å markedsføre Nutramigen 2 med LGG, som er en melkeerstatning for spedbarn mellom fire og seks måneder som er allergiske mot kumelk og soyaproteiner. Den 13. desember 2006 Mead Johnson Nutritionals på vedtaket fra Mattilsynet. Mattilsynet videresendte klagen fra selskapene og ba VKMs faggrupper for hygiene og smittestoffer samt ernæring, dietetiske produkter, ny mat og allergi om å foreta en ny risikovurdering basert på nye data som er lagt frem i forbindelse med klagen

Use of Robotized DNA Isolation and Real-Time PCR To Quantify and Identify Close Correlation between Levels of Neisseria meningitidis DNA and Lipopolysaccharides in Plasma and Cerebrospinal Fluid from Patients with Systemic Meningococcal Disease

The present study, using robotized DNA isolation and quantitative PCR based on the Neisseria meningitidis-specific capsular transport A gene, demonstrates the ease, rapidity, specificity, and sensitivity of quantifying neisserial DNA in plasma (n = 65) and cerebrospinal fluid (CSF) (n = 12) from patients with systemic meningococcal disease. We found a close correlation between the levels of neisserial DNA and lipopolysaccharides in plasma (r = 0.905) and in CSF (r = 0.964). The median concentration of neisserial DNA in plasma in 23 patients with persistent shock was 2 × 10(7) copies/ml, versus <10(3) copies/ml in 42 nonshock patients. Furthermore, quantitative PCR made possible estimates of the total number of meningococci in plasma, as opposed to conventional blood cultures, suggesting about 1,000 dead meningococci for every viable bacterium. Finally, with logistic regression analyses, neisserial DNA may predict a patient's disease severity and outcome at hospital admission. The number of meningococci in plasma and CSF appears to be the main determinant of the lipopolysaccharide levels, clinical presentation, and outcome

Impact of extensive antibiotic treatment on faecal carriage of antibiotic-resistant enterobacteria in children in a low resistance prevalence setting

We prospectively studied the consequences of extensive antibiotic treatment on faecal carriage of antibiotic-resistant enterobacteria in a cohort of children with cystic fibrosis (CF) and a cohort of children with cancer compared to healthy children with no or low antibiotic exposure. The study was conducted in Norway in a low resistance prevalence setting. Sixty longitudinally collected faecal samples from children with CF (n = 32), 88 samples from children with cancer (n = 45) and 127 samples from healthy children (n = 70) were examined. A direct MIC-gradient strip method was used to detect resistant Enterobacteriaceae by applying Etest strips directly onto agar-plates swabbed with faecal samples. Whole genome sequencing (WGS) data were analysed to identify resistance mechanisms in 28 multidrug-resistant Escherichia coli isolates. The prevalence of resistance to third-generation cephalosporins, gentamicin and ciprofloxacin was low in all the study groups. At inclusion the prevalence of ampicillin-resistant E. coli and trimethoprim-sulfamethoxazole-resistant E. coli in the CF group compared to healthy controls was 58.6% vs. 28.4% (p = 0.005) and 48.3% vs. 14.9% (p = 0.001), respectively, with a similar prevalence at the end of the study. The prevalence of resistant enterobacteria was not significantly different in the children with cancer compared to the healthy children, not even at the end of the study when the children with cancer had been treated with repeated courses of broad-spectrum antibiotics. Children with cancer were mainly treated with intravenous antibiotics, while the CF group mainly received peroral treatment. Our observations indicate that the mode of administration of antibiotics and the general level of antimicrobial resistance in the community may have an impact on emergence of resistance in intestinal enterobacteria during antibiotic treatment. The WGS analyses detected acquired resistance genes and/or chromosomal mutations that explained the observed phenotypic resistance in all 28 multidrug-resistant E. coli isolates examined

Salmonella diarizonae hos dyr i Norge Konsekvenser for dyr og mennesker. Uttalelse av Faggruppe for hygiene og smittestoffer og Faggruppe for dyrehelse og dyrevelferd (dyrevern)

publishedVersio

Risk assessment on the use of triclosan in cosmetics; Development of antimicrobial resistance in bacteria - II. Opinion of the Panel on Biological Hazards Norwegian Scientific Committee for Food Safety

Den Europa kommisjonens vitenskapskomité for forbruksvarer (SCCP) konkluderte 10. oktober 2006 med at det på grunnlag av tilgjengelige data ikke er funnet bevis for at triklosan i kosmetiske produkter kan føre til resistens – eller kryssresistensutvikling hos bakterier. Til tross for at en slik sammenheng kan være sannsynlig, finnes det ikke god dokumentasjon. Siden denne konklusjonen ikke svarer til Vitenskapskomiteen for mattrygghets (VMK) konklusjon av 31. januar 2005, har Mattilsynet bedt VMK om på nytt å vurdere konklusjonen i lys av SCCPs rapport og nyere litteratur. I denne rapporten konkluderer faggruppe for hygiene og smittestoffer ved VMK med at verken SSCPs rapport eller nyere litteratur gir grunnlag for å endre konklusjonen av 31. januar 2005. Tvert imot synes nyere litteratur å underbygge konklusjonen. Dilemmaet er at den dagen det foreligger dokumentasjon på resistensutvikling hos klinisk relevante bakterier som en følge av triklosanbruk, kan det være for sent for å avgrense problemet på en effektiv måte. Antimikrobielle stoffer som triklosan bør derfor bare benyttes i tilfeller der vitenskapelig dokumentasjon bekrefter at bruken gir en klar helsegevinst. Slik dokumentasjon etterlyses

Salmonella diarizonae hos dyr i Norge. Konsekvenser for dyr og mennesker.

S. diarizonae er et subspecies av Salmonella som påvises endemisk hos sau i enkelte regioner i Norge. Det er derfor stilt spørsmål om mikrobens potensielle og reelle betydning for både folke- og dyrehelsen. Det er også stilt spørsmål ved påstanden om at Norge har en tilnærmet salmonella-fri husdyrpopulasjon kan forsvares når S. diarizonae påvises relativt ofte hos sau i Norge i dag. Mattilsynet har på ovennevnte bakgrunn bedt Vitenskapskomiteen for mattrygghet (VKM) om en risikovurdering. Det ble en ad hoc arbeidsgruppe nedsatt for å gjennomføre oppdraget. Vurderingen er utført av faggruppe for hygiene og smittestoffer ved VKM

A qualitative assessment of the risks of transmission of microorganisms to humans resulting from the consumption of raw milk and raw cream in Norway. Panel for Biological Hazards, Norwegian Scientific Committee for Food Safety

publishedVersio